- Category
- Micro (2024-25)
- Udyam number
- UDYAM-MH-19-0028147

A-Mark Pharma Private Limited
About A-Mark Pharma Private Limited
Data last updated:
A-Mark Pharma Private Limited is a private limited company based in Mumbai, Maharashtra, India. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 17 February 2011 and has been in existence for over 15 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24233MH2011PTC213660. Its GSTIN is 27AAJCA5460E1ZR (Maharashtra).
The company has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹10 Lakh. It is led by directors Shilpi Mandhana and Suresh Mandhana.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Mumbai, Maharashtra.
As per the financials filed for FY 2025, the company reported a revenue of ₹5.25 Cr, a decline of 5% compared to the previous year. For the same year it recorded a net profit of ₹86,267 (net margin 0.2%) and EBITDA of ₹1.71 Lakh (EBITDA margin 0.3%).
Court records list 3 cases involving the company, including 3 filed against it; 1 case is pending.
A-Mark Pharma Private Limited is registered as a micro enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-19-0028147). The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Recognitions & Rankings of A-Mark Pharma
Contact details
A-Mark Pharma Private Limited's registered office is in Mumbai, Maharashtra. Its e-mail address is in the company report.
- Email
- Registered Address411 Atlanta Estate Premises Co – Op. Society Limited G. M. Link Road Near Virwani Goregaon, (East), Mumbai, Maharashtra, India – 400063
- IndustryPharma, Pharmaceutical Retailers & Distributors
To see the full contact details of A-Mark Pharma Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of A-Mark Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
Financials of A-Mark Pharma Private Limited
FY 2025 filings availableA-Mark Pharma Private Limited reported revenue of ₹5.25 Cr (down 5% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue fell 5% in the latest year. EBITDA fell 51% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹1.71 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹86,267 | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 0.3% | ||||
| Net Profit Margin | 0.2% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of A-Mark Pharma Private Limited, buy the company report.
Board of directors of A-Mark Pharma Private Limited
A-Mark Pharma has 2 current directors and 1 former director. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Shilpi Mandhana | Director | 17 Feb 2011 | 15 Years 9 Months | Current |
| Suresh Mandhana Also directs: Chemserves Pharma Private Limited, Relichem Pharma Private Limited | Director | 25 Jan 2022 | 4 Years 9 Months | Current |
Auditor
A-Mark Pharma Private Limited is audited by BAKLIWAL & CO for the financial year 2021.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| BAKLIWAL & CO | FY 2021 | 130381W |
Shareholding
The shareholding of A-Mark Pharma Private Limited is on record for 5 financial years, the latest being FY 2021, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2021 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of A-Mark Pharma Private Limited, buy the company report.
Legal cases
A-Mark Pharma Private Limited has 3 court cases on record: 3 filed against it. 1 case is pending and 2 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 3 | 3 | 1 |
Cases on record (3 of 3)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Mumbai CMM Courts, Maharashtra | Court case (Summary case) | Filed against the company by Paari Chem Resources LLP Through Swati Gopal Jadhav | Pending |
| District court, Vadodara, Gujarat | Criminal complaint | Filed against the company by Sapna Chemicals Through Prop Mehul Shah | Disposed |
| District court, Mumbai CMM Courts, Maharashtra | Interim or miscellaneous application | Filed against the company by an individual | Disposed |
To see the full case history of A-Mark Pharma Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for A-Mark Pharma Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
A-Mark Pharma has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAJCA5460E1ZR | Maharashtra | Active | 03 Dec 2020 |
To see the full GST registrations and return filing status of A-Mark Pharma Private Limited, buy the company report.
Recent activity
A-Mark Pharma Private Limited has 4 board changes on record since 2011: 3 appointments and 1 cessation. The latest: Rohitash Kailashchand Mandhana ceased to be Director on 25 Jan 2022.
Frequently asked questions
A-Mark Pharma is an active private limited company based in Mumbai, Maharashtra, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 17 February 2011 (15+ years old) and is registered under CIN U24233MH2011PTC213660.
A-Mark Pharma has 2 current directors:
- Shilpi Mandhana - Director
- Suresh Mandhana - Director
The latest financial statements of A-Mark Pharma on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of A-Mark Pharma is 27AAJCA5460E1ZR, registered in Maharashtra.
The CIN (Corporate Identification Number) of A-Mark Pharma is U24233MH2011PTC213660. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
A-Mark Pharma has 3 court cases on record: 3 filed against it. 1 is pending.
A-Mark Pharma was incorporated on 17 February 2011, making it 15+ years old. It is registered with the Registrar of Companies, Mumbai.
Rohitash Kailashchand Mandhana ceased to be Director on 25 Jan 2022. Suresh Mandhana was appointed as Director on 25 Jan 2022. Rohitash Kailashchand Mandhana was appointed as Director on 17 Feb 2011. A-Mark Pharma has 4 board changes on record in total.
Yes, A-Mark Pharma is registered as a micro enterprise under Udyam registration (number: UDYAM-MH-19-0028147).
The registered office of A-Mark Pharma is at 411 Atlanta Estate Premises Co – Op. Society Limited G. M. Link Road Near Virwani Goregaon, East, Mumbai, Maharashtra, India – 400063.

